Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
19.32
+0.45 (2.38%)
Jun 8, 2026, 10:19 AM EDT - Market open
Aktis Oncology Revenue
Aktis Oncology had revenue of $3.23M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $8.28M, up 1,394.04% year-over-year. In the year 2025, Aktis Oncology had annual revenue of $6.50M with 336.92% growth.
Revenue (ttm)
$8.28M
Revenue Growth
+1,394.04%
P/S Ratio
126.02
Revenue / Employee
$104,772
Employees
79
Market Cap
1.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.50M | 5.01M | 336.92% |
| Dec 31, 2024 | 1.49M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAKTS News
- 4 days ago - Aktis Oncology Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 5 days ago - Aktis Oncology price target raised to $35 from $33 at H.C. Wainwright - TheFly
- 11 days ago - Aktis Oncology to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 12 days ago - Aktis Oncology Transcript: Status update - Transcripts
- 12 days ago - Aktis Oncology Slides: Status update - Filings
- 17 days ago - Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors - GlobeNewsWire
- 25 days ago - Aktis Oncology Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 27 days ago - Aktis Oncology reports Q1 revenue $3.23M, consensus $1.85M - TheFly